ARYx Therapeutics Inc is a product-driven biopharmaceutical company that leverages its expertise and intellectual property to develop a range of internally discovered drug candidates. Their primary goal is to address safety concerns associated with widely used, commercially successful drugs. By focusing on retrometabolic drug design, ARYx aims to improve the safety profile of oral therapies for chronic diseases, offering potential benefits to patients worldwide.